Gan & Lee Pharmaceuticals Beheer

Beheer criteriumcontroles 4/4

De CEO Gan & Lee Pharmaceuticals is Kai Du, benoemd in Jul2020, heeft een ambtstermijn van 4.33 jaar. bezit rechtstreeks 0.087% van de aandelen van het bedrijf, ter waarde CN¥ 24.11M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.3 jaar en 4.6 jaar.

Belangrijke informatie

Kai Du

Algemeen directeur

CN¥1.0m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	4.3yrs
Eigendom CEO	0.09%
Management gemiddelde ambtstermijn	4.3yrs
Gemiddelde ambtstermijn bestuur	4.6yrs

Recente managementupdates

Recent updates

CEO

Kai Du (47 yo)

4.3yrs

Tenure

CN¥1,041,900

Compensatie

Mr. Kai Du is General Manager of Gan & Lee Pharmaceuticals. since July 20, 2020 and has been its Director since April 26, 2019.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Gan Zhongru	Founder & Chairman	26.8yrs	CN¥457.20k	35.48% CN¥ 9.8b
Kai Du	GM & Director	4.3yrs	CN¥1.04m	0.087% CN¥ 24.1m
Cheng Sun	CFO & Deputy GM	4.3yrs	CN¥695.20k	0.089% CN¥ 24.6m
Wei Chen	Deputy GM & Director	less than a year	CN¥892.20k	0.087% CN¥ 24.1m
Weiqiang Song	Deputy GM & Director	8.8yrs	CN¥960.50k	0.087% CN¥ 24.1m
Rong Zou	Secretary	6.9yrs	CN¥695.00k	0.087% CN¥ 24.1m
Cheng Xing	Deputy General Manager	4.3yrs	CN¥752.80k	0.087% CN¥ 24.1m
Zifei Yuan	Deputy General Manager	4.3yrs	CN¥710.50k	0.087% CN¥ 24.1m
Zhi Li	Deputy General Manager	less than a year	geen gegevens	geen gegevens

4.3yrs

Gemiddelde duur

42yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 603087 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Gan Zhongru	Founder & Chairman	26.8yrs	CN¥457.20k	35.48% CN¥ 9.8b
Kai Du	GM & Director	5.6yrs	CN¥1.04m	0.087% CN¥ 24.1m
Wei Chen	Deputy GM & Director	3.2yrs	CN¥892.20k	0.087% CN¥ 24.1m
Weiqiang Song	Deputy GM & Director	9.2yrs	CN¥960.50k	0.087% CN¥ 24.1m
Jiao Jiao	Director	3.7yrs	CN¥1.04m	0.045% CN¥ 12.5m
Lei Yin	Director	3.7yrs	CN¥897.10k	0.020% CN¥ 5.6m
Yanqing He	Independent Director	5.6yrs	CN¥72.00k	geen gegevens
Guojun Zheng	Independent Director	5.6yrs	CN¥72.00k	geen gegevens
Yi Wang	Supervisor	3.7yrs	geen gegevens	geen gegevens
Tao Zhang	Chairman of the Board of Supervisors	3.2yrs	geen gegevens	geen gegevens
Jiaxin Wang	Supervisor	5.6yrs	geen gegevens	geen gegevens
Zengyi Chang	Independent Director	2.5yrs	CN¥72.00k	geen gegevens

4.6yrs

Gemiddelde duur

44.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 603087 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.6 jaar).

Gan & Lee Pharmaceuticals Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Gan & Lee Pharmaceuticals., Annual General Meeting, May 16, 2024

Less than half of directors are independent

Recent updates

Gan & Lee Pharmaceuticals Announces Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks

Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults

Third quarter 2024 earnings released: EPS: CN¥0.34 (vs CN¥0.23 in 3Q 2023)

Gan & Lee Pharmaceuticals. to Report Q3, 2024 Results on Oct 23, 2024

Investor sentiment improves as stock rises 18%

Gan & Lee Pharmaceuticals. (SHSE:603087) announces an Equity Buyback for CNY 300 million worth of its shares.

Second quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.15 in 2Q 2023)

Gan & Lee Pharmaceuticals. to Report First Half, 2024 Results on Aug 29, 2024

Gan & Lee Pharmaceuticals., Annual General Meeting, May 16, 2024

First quarter 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.09 in 1Q 2023)

Gan & Lee Pharmaceuticals. to Report Q1, 2024 Results on Apr 25, 2024

Gan & Lee Pharmaceuticals. to Report Fiscal Year 2023 Results on Apr 25, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: CN¥0.23 (vs CN¥0.39 loss in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.55 loss in 2Q 2022)

First quarter 2023 earnings released: EPS: CN¥0.09 (vs CN¥0.20 in 1Q 2022)

Gan & Lee Pharmaceuticals.(XSSC:603087) dropped from FTSE All-World Index (USD)

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.39 loss per share (vs CN¥0.90 profit in 3Q 2021)

Gan & Lee Pharmaceuticals. announced that it expects to receive CNY 813.6 million in funding

Second quarter 2022 earnings released: CN¥0.55 loss per share (vs CN¥0.32 profit in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.34 in 1Q 2021)

Gan & Lee Pharmaceuticals Co., Ltd. Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for a Novel Glucagon-Like Peptide-1 Analogue, GZR18

Third quarter 2021 earnings released: EPS CN¥0.90 (vs CN¥0.70 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.34 in 2Q 2020)

Gan & Lee Pharmaceuticals Co., Ltd. Announces Positive Phase 1 Clinical Trial Results at the 81st Scientific Sessions of the American Diabetes Association

First quarter 2021 earnings released: EPS CN¥0.34 (vs CN¥0.24 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥2.31 (vs CN¥2.31 in FY 2019)

New 90-day low: CN¥121

FDA Grants Fast Track Designation for Gan & Lee Pharmaceuticals Co., Ltd.'s GLR2007, for the Treatment of Patients with Glioblastoma

Investor sentiment improved over the past week

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd